April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Endothelial-Specific and Drug-Inducible βcap73 Expression Impairs Retinal Microvascular Remodeling in a Mouse Model of Retinopathy of Prematurity
Author Affiliations & Notes
  • J. T. Durham
    Physiology, Tufts University School of Medicine, Boston, Massachusetts
  • I. M. Herman
    Physiology, Tufts University School of Medicine, Boston, Massachusetts
  • Footnotes
    Commercial Relationships  J.T. Durham, None; I.M. Herman, US Patent #6,780,987, P.
  • Footnotes
    Support  NIH EY15125, EY19533 (IMH), T32-DK07542 (JTD)
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 3654. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. T. Durham, I. M. Herman; Endothelial-Specific and Drug-Inducible βcap73 Expression Impairs Retinal Microvascular Remodeling in a Mouse Model of Retinopathy of Prematurity. Invest. Ophthalmol. Vis. Sci. 2010;51(13):3654.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Retinal capillary endothelial cell (RCEC) migration, a critical step in angiogenesis, is driven by cytoskeletal remodeling, and is mainly achieved by the dynamic regulation of the β-actin network. Previous work reveals that the β-actin network is enriched in motile cytoplasm of RCEC during microvascular morphogenesis, and is modulated by the isoactin-specific capping protein, βcap73. We predict that regulated RCEC βcap73 over-expression could disrupt angiogenesis by perturbing β-actin-dynamics. Indeed, recent work has shown that adenoviral-βcap73 RCEC infection disrupts cytoskeletal architecture, inhibits motility and morphogenesis, and, induces anoikis, or detachment-dependent apoptosis.

Methods: : We are validating our in vitro work with a ‘two-mouse’ transgenic approach in retinopathy of prematurity (ROP) studies. We have subcloned βcap73 into a tetracycline-inducible vector, pTRE2, and confirmed expression using cell culture transfection. Using this vector, we have established several transgenic lines, and crossed these mice with a second strain that express the tetracycline transactivator under the control of an endothelial-specific promoter to achieve endothelial-specific and drug-inducible βcap73 in offspring positive for both transgenes.

Results: : Cells co-transfected with the pTet-On and pTRE2-βcap73 vectors express a myc-tagged version of this molecule when exposed to 1µg/ml of doxycycline. Earliest protein expression occurs at 6h post drug addition, and persists up to 48h. Also, cells over-expressing βcap73 undergo a marked morphogenic alteration compared to non-transfected cells. Preliminary data reveal that in our double transgenic mice, neovascular tuft formation is impaired by 41% in the mouse ROP model.

Conclusions: : Our preliminary findings suggest that endothelial-specific targeting and βcap73 over-expression may represent an innovative therapeutic approach capable of abrogating pathologic ocular angiogenesis that accompanies wet age-related macular degeneration or diabetic retinopathy.

Keywords: retinal neovascularization • gene/expression • cytoskeleton 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×